The pharmacy discovered an impurity called dimethylformamide, which is classified as a probable carcinogen by the World Health Organization.
The impurity was found in valsartan manufactured by five companies, including Novartis. The online pharmacy recommended a recall.
The FDA will evaluate Valisure’s findings.
Dozens of forms of generic valsartan have been recalled since July 2018, after an impurity known as N-Nitrosodimethylamine was detected in a version of the drug.
Dimethylformamide is the fourth potential carcinogen to be found in generic versions of the heart pills.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
